ALMR vs TECH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALMR and TECH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALMR and TECH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.

Full ALMR guide

Bio-Techne Corporation is a global life-sciences tools and diagnostics company based in Minnesota. It supplies the reagents, proteins, antibodies, immunoassays, and analytical instruments that biopharma and academic researchers use in drug discovery, cell and gene therapy, and diagnostics. The portfolio spans three customer-facing brands (R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics) and is reported in two segments: Protein Sciences, the larger piece at roughly three-quarters of revenue, and Diagnostics and Spatial Biology, roughly the remaining quarter. Because it sells the consumables and instruments that sit upstream of research and manufacturing, Bio-Techne's results track biopharma and academic funding cycles rather than any single end product, with growth pockets in GMP proteins for cell therapy and its COMET spatial-biology platform.

Full TECH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALMR drivers: Consumable pull-through per instrument; Installed base expansion.
• TECH drivers: Pending Merck KGaA acquisition; Spatial biology and higher-value platforms.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. For TECH, the central risk is deal-specific: because the stock trades near the $73 cash offer, a failure to close (from regulatory objections, the shareholder vote, or a change in conditions) could send shares back toward pre-announcement levels, while the upside above the deal price is limited.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALMR if you believe its drivers more; TECH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALMR and TECH guides.

ALMR. There is no meaningful price to earnings ratio here because the company loses money, so the market is working off revenue multiples: about 23 times trailing sales, or closer to 20 times the 2026 guide once the cash balance is netted out. That is in the range life-science tools investors pay for a platform growing north of 50% with widening gross margin, and it assumes the consumable annuity keeps building. The IPO priced at $17 in April 2026 and opened at $22.60, so the shares have roughly doubled from the offer price in four months, most of that in a single 31% session after the second-quarter report.

TECH. Figures are approximate and tied to the asOf date; verify live numbers and the current status of the Merck KGaA transaction before acting. Because the stock trades near the $73 cash offer, traditional valuation multiples matter less than the merger: the return an investor earns from here is largely the spread between the market price and the deal price, adjusted for the odds and timing of closing. If the deal completes, holders receive $73 per share in cash; if it breaks, the stock would re-rate to standalone fundamentals.

Headline figures (approximate, August 2026): ALMR shows revenue (ttm) ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year, 2026 revenue guidance ~$116 million to $120 million, ~59% growth at the midpoint, gross margin (q2 2026) ~60%, up from ~53% a year earlier, net loss (q2 2026) ~$13.2 million, on ~$31.2 million of operating expenses (~$13.8 million R&D, ~$17.4 million SG&A); TECH shows situation Pending acquisition by Merck KGaA at $73 per share in cash (announced June 25, 2026); verify live figures and deal status before acting, enterprise value of deal ~$11.3 billion, roughly a 36% premium to the prior one-month average price, recent share price Trading near the low $70s, close to the cash offer, which caps upside and signals the market is pricing deal completion, market cap ~$11 billion (approximate; moves with the deal spread).

ALMR and TECH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALMR and TECH exposure against your real portfolio. It is not an investment adviser.